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A stereocontrolled procedure is reported for the access of various fluorine-containing
piperidine and azepane β-amino esters. The synthetic protocol starts from readily available
unsaturated cycloalkene β-amino acids and is based on oxidative cleavage of the ring olefin bond
followed by ring closing of the diformyl intermediates in the presence of some fluorine-containing
amines across reductive amination.
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Introduction
Cyclic β-amino acids are considered to be novel compounds in the field of synthetic and
medicinal chemistry and they have exerted increasing interest during the past twenty years because
of the importance of some antifungal, antibacterial or analgetic small molecules. For example,
(1R,2S)-2-aminocyclopentanecarboxylic acid (cispentacin, 1), (1R,2S)-2-amino-4-
methylenecyclopentanecarboxylic acid (icofungipen, 2),  BAY  Y9379  (3), (2R,3S)-3-
aminooxetane-2-carboxylic acid (oxetin, 4) or tilidin (5) are a few of some highly functionalized
derivatives in drug research (Figure 1, 1-5). These compounds are of high significance because
they are key elements of various bioactive products with antitumoral, antibacterial, antiviral and
cardioprotective activities. As conformationally restricted building blocks, these small molecules
are of appreciable importance for the synthesis of peptides and, accordingly, they exert a
considerable impact in the fields of biomolecules and drug design.1
Figure 1. Some small cyclic β-amino acids with pharmaceutical relevance.
Azaheterocyclic β-amino acids, which express high biological relevance, represent an
important class of compounds in both medicinal and organic chemistry. Thus, several piperidine
and pyrrolidine β-amino acid derivatives exhibit antiviral or antibacterial activities (Figure 2, 6-
8).1
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Figure 2. Some azaheterocyclic β-amino acids with biological importance.
Organofluorine compounds have generated increasing attention in the field of
pharmaceuticals and agrochemicals over the last decade.2 Among the ever-increasing number of
fluorine-containing biomolecules or building blocks, a number of fluorinated open-chain α-, β- or
γ-amino acids exhibit antitumoral or antibiotic properties.3
Figure 3. Several molecules with fluoroamine or trifluoroamine units.
Molecules containing β-fluorinated or β-trifluorinated amine moieties are important entities
in pharmaceutical chemistry or agrochemistry.2,4 Accordingly, fluorine-containing five- or six-
membered azaheterocycles, which are components in drugs such as MK-0657, MK-0731 or
neceprevir, are of high importance in medicinal chemistry.5 However, fluorine-containing seven-
membered N-heterocycles are relatively less abundant in the literature.
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Despite of this, they might gain high relevance in the future, which is due to the important
role of some functionalized counterparts in drug research.6 Fluorine-containing
tetrahydroisoquinoline derivatives and other types of N-fluoroalkylated molecular scaffolds are
known to possess important biologically properties.7 β-Fluoroamine or β-trifluoroamine units are
also present in versatile fluorine-containing amino acid derivatives of biological relevance (Figure
3, 9-13).8
Fluorine-containing saturated N-heterocycles are of special significance, since introduction
of one or more fluorine atoms into the skeleton of an azaheterocycle can increase lipophilicity and
metabolic stability. Moreover, fluorine substitution may reduce basicity and, accordingly, it
provides better bioavailability to a certain molecule. Moreover, perfluorocarbons are characterized
by biological inertness, however they exhibit intense hydrophobic and lipophilic effects.
Results and Discussion
Because of the high biological importance of saturated azaheterocycles, our current ai was
to combine β-amino acid and organofluorine molecular entities and synthesize novel molecular
structures. This manuscript is intended to offer an insight into the extension of our earlier work9a
based on stereocontrolled synthesis of fluorine-containing piperidine or azepane β-amino acid
derivatives. The synthetic approach included the use of some commercially available fluorinated
or polyfluorinated primary amines and was based on the oxidative ring cleavage of unsaturated
cyclic β-amino esters through the ring olefin bond (through vicinal diol). It is followed by ring
closing by double reductive amination giving the products across ring expansion of the diformyl
intermediates.9
Cyclopentene cis-β-amino acid (±)-14 was first converted by esterification according to the
route described earlier10, followed by N-protection and cis-dihydroxylation with the OsO4/NMO
system to the corresponding dihydroxylated cis amino ester (±)-15. This diol was submitted to
oxidative ring opening with NaIO4 in THF/H2O affording the corresponding acylic diformyl amino
ester (±)-16. This relatively unstable dialdehyde derivative was further used in the forthcoming
step without isolation. Thus (±)-16 was subjected to double-reductive amination with various
commercially available fluorinated primary amines such as 2,2,3,3,4,4,5,5,5-nonafluoropentan-1-
amine, 2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptan-1-amine and 1,1,1-trifluoropropan-2-amine.
The reaction was induced with NaBH3CN  in  the  presence  of  CH2Cl2. Ring closing involves
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reductive amination and gives the corresponding fluorinated or perfluorinated cis β-amino esters
with a piperidine ring system ((±)-17a-c) (Scheme 1).








Table 1. Synthesis of piperidine cis-β-amino esters 17a-c.
Since the configuration of the stereocenters at C-1 and C-2 of amino esters (±)-14 and (±)-
15 were not affected during the ring closing procedure, the integrity of the configuration of the
chiral centers in (±)-17a-c was conserved, that is configurations are predetermined by the structure
of the starting materials.
Accordingly, cis amino ester provided the corresponding piperidine derivative with the
carboxylate and carbamate functions at C-3 and C-4 in a cis relative arrangement (Scheme 1, Table
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1). Noteworthy, that the cyclization reaction performed with 1,1,1-trifluoropropan-2-amine as the
amine source containing a chiral center yielded only a single piperidine compound ((±)-17b).
In continuation, cis isomer (±)-15 was converted to cyclopentene trans-β-amino acid (±)-
189a,10 in an analogous way. Namely, compound (±)-15 with the ester and the carbamate groups in
a trans relationship was subjected to oxidative ring opening with NaIO4.







Table 2. Synthesis of piperidine trans-β-amino esters 20a-b.
The formed instable dialdehyde intermediate (±)-19 was treated with fluorinated amines
and NaBH3CN in CH2Cl2 without isolation furnishing fluorinated piperdine trans amino esters (±)-
20a,b (Scheme 2, Table 2). Note, contrary to its cis counterpart compound (±)-20a proved to be
unstable. Again, the reaction took place with stereocontrol with the conservation of the
configuration of the chiral centers C-1 and C-2 of (±)-18 corresponding to C-3 and C-4 in products
(±)-20a,b (Scheme 2, Table 2).
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The synthetic procedure presented above was further extended to the efficient access of
fluorinated azepane β-aminocarboxylic esters. For example, cis-β-aminocyclohex-4-
enecarboxylates (±)-21 undergoing esterification, N-benzoylation and cis-dihydroxylation with
NMO/OsO49a,11 resulted in the corresponding vicinal cis diol derivatives (±)-22. Subsequently, this
dihydroxylated ester was transformed via oxidative ring cleavage and ring expansion. The latter
step involved reductive amination with commercially available fluorinated or perfluorinated
primary amines (see Table 3) in the presence of NaBH3CN. The process proceeds through
stereocontrol affording the corresponding cis azepane amino esters (±)-24a-e (Scheme 3).
Thus, applying the oxidative ring opening/ring closure with reductive amination protocol, a series
of mono-, di- or trifluorinated as well as perfluorinated seven-membered N-heterocyclic cis amino
esters could be accessed.
Scheme 3. Synthesis of fluorinated azepane β-amino esters.
Conclusions
A simple stereocontrolled synthetic route has been developed for the preparation of novel
fluorine-containing six- and seven-membered N-heterocyclic β-amino esters, based on olefin bond
oxidative ring cleavage of cyclopentene and cyclohexene β-amino acids, followed by ring closing
with double reductive amination of diformyl intermediates in the presence of commercially
available primary fluoroamines. Since the stereocenters of the starting carbocyclic β-amino esters
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are not affected during the process, they will predetermine the configuration of the chiral centers










Table 3. Synthesis of azepane β-amino esters 24a-e.
Experimental Section
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General procedure for the synthesis of fluorine-containing N-heterocyclic β-amino esters by
oxidative ring cleavage followed by reductive amination
To a stirred solution of β-amino ester (2 mmol) NaIO4 (1.5 equiv) was added in THF/H2O (25 mL/2
mL). After stirring for 1 h at 20 °C under argon atmosphere, H2O was added (40 mL). Then the
mixture was extracted with CH2Cl2 (3×20 mL) and the combined extract was dried over Na2SO4.
The crude dialdehyde product was immediately used for reductive amination without purification.
Fluorinated or polyfluorinated amines (1 equiv) were added to the solution in CH2Cl2 (30 mL) and
the mixture was stirred at 20 °C for 10 minutes. Next NaBH3CN (1 equiv) and AcOH (2 drops)
were added and stirring was continued for another 4 h at 20 °C. Then the reaction mixture was
diluted with H2O (20 mL) and extracted with CH2Cl2 (3×20 mL). The combined organic layer was
dried (Na2SO4) and concentrated under vacuum. The crude product was purified by column
chromatography on silica gel (n-hexane/EtOAc).
(3R*,4R*)-Ethyl 3-(((benzyloxy)carbonyl)amino)-1-(2,2,3,3,4,4,5,5,5-nonafluoropentyl)-
piperidine-4-carboxylate, (±)-17a
Yellow oil; yield: 13% (126 mg); Rf = 0.75 (n-hexane/acetone 4:1); 1H-NMR (500 MHz, CDCl3):
δ = 1.22 (t, J = 7.0 Hz, 3H, CH3), 1.73-1.80 (m, 1H, H-5), 1.93-2.05 (m, 1H, H-5), 2.45-2.55 (m,
2H, H-2, H-6), 2.67-2.72 (m, 1H, H-4), 2.88-2.94 (m, 2H, H-2, H-6), 3.06 (t, J = 16.1 Hz, 2H,
NCH2), 4.05-4.15 (m, 2H, CH2CH3) 4.28-4.34 (m, 1H, H-3), 5.07 (s, 2H, OCH2), 5.56 (brs, 1H, N-
H), 7.28-7.39 (m, 5H, Ar-H); 13C-NMR (126 MHz, CDCl3): δ = 14.1, 23.8, 43.6, 47.8, 52.9, 56.7
(t, 2JC,F = 22.5 Hz, C(CF2)5), 58.8, 60.9, 66.7, 107.6-120.8 (m, 4 C, (CF2)5CF3), 127.9, 128.0, 128.5,
136.6, 155.6, 172.4; 19F-NMR (471 MHz, CDCl3): δ = -80.9 (t, J = 9.4 Hz), -115.8, -124.1, -126.2.














Yellow oil; yield: 15% (210 mg); Rf = 0.41 (n-hexane/EtOAc 4:1); 1H-NMR (400 MHz, CDCl3):
δ = 1.23 (t, J = 7.0 Hz, 3H, CH3), 1.70-2.04 (m, 2H, H-5), 2.41-3.17 (m, 6H, H-2, H-6, NCH2),
4.07-4.21 (m, 3H, CH2CH3, H-4), 5.10 (s, 2H, OCH2), 5.21-5.34 (m, 1H, H-3), 7.28-7.47 (m, 6H,
Ar-H, N-H); 19F-NMR (376 MHz, CDCl3): δ = -80.9 (t, J = 7.5 Hz), -115.8, -124.1, -126.1.
(3R*,4R*)-Ethyl 3-(((benzyloxy)carbonyl)amino)-1-(1,1,1-trifluoropropan-2-yl)piperidine-4-
carboxylate, (±)-17b
Yellow oil; yield: 14% (111 mg); Rf = 0.24 (n-hexane/EtOAc 4:1); 1H-NMR (400 MHz, CDCl3):
δ = 1.08-1.19 (m, 6H, CH3), 1.53-1.62 (m, 1H, H-5), 1.82-1.98 (m, 1H, H-5), 2.53-2.95 (m, 4H, H-
2, H-6), 3.35-3.51 (m, 1H, H-4), 3.88-4.03 (m, 2H, CH2CH3), 4.03-4.27 (m, 2H, H-3, NCH), 4.95-
5.08 (m, 2H, OCH2), 6.79 (brs, 1H, N-H), 7.29-7.41 (m, 5H, Ar-H), 13C-NMR (100 MHz, CDCl3):
δ = 14.7, 14.8, 24.2, 44.2, 48.6, 49.7, 52.9, 59.5, 60.0 (q, 2JC,F = 23.3 Hz, CCF3), 60.6, 66.0, 117.7,
128.4, 128.6, 129.1, 138.2, 151.9, 172.8; 19F-NMR (376 MHz, CDCl3): δ = -70.1 (t, J = 11.3 Hz);
MS: (ESI) m/z = 403.41 (M+1).
(3R*,4S*)-Ethyl 3-(((benzyloxy)carbonyl)amino)-1-(1,1,1-trifluoropropan-2-yl)piperidine-4-
carboxylate, (±)-20b
Colorless oil; yield: 26% (300 mg); Rf = 0.48 (n-hexane/EtOAc 1:4); 1H-NMR (500 MHz, CDCl3):
δ = 1.17-1.27 (m, 6H, CH3), 1.83-1.96 (m, 2H, H-5), 2.35-2.88 (m, 4H, H-2, H-6), 2.99-3.02 (m,
2H, H-4, NCH), 3.97-4.08 (m, 1H, H-3), 4.10-4.20 (m, 2H, CH2CH3), 5.09 (m, 2H, OCH2), 5.16
(brs, 1H, N-H), 7.28-7.40 (m, 5H, Ar-H); 13C-NMR (126 MHz, CDCl3): δ = 10.5, 14.2, 26.2, 45.3,
46.3, 48.9, 52.2, 60.5 (q, 2JC,F = 26.9 Hz, CCF3), 60.8, 66.8, 125.7 (q, 1JC,F =288.5 Hz, CF3) , 128.2,
128.5, 136.4, 155.4, 172.7; 19F-NMR (471 MHz, CDCl3): δ = -71.4.




Yellow oil; yield: 21% (125 mg); Rf = 0.58 (n-hexane/EtOAc 2:1); 1H-NMR (500 MHz, CDCl3):
δ = 1.22 (t, J = 7.0 Hz, 3H, CH3), 1.74-1.83 (m, 1H, H-5), 1.93-2.04 (m, 1H, H-5), 2.45-2.56 (m,
2H, H-2, H-6), 2.67-2.74 (m, 1H, H-4), 2.88-2.97 (m, 2H, H-2, H-6), 3.07 (t, J = 15.5 Hz, 2H, N-
CH2), 4.06-4.14 (m, 2H, CH2CH3) 4.29-4.37 (m, 1H, H-3), 5.07 (s, 2H, OCH2), 5.57 (brs, 1H, N-
H), 7.27-7.39 (m, 5H, Ar-H); 13C-NMR (126 MHz, CDCl3): δ = 14.1, 23.8, 43.6, 47.8, 52.9, 56.7
(t, 2JC,F = 22.0 Hz, C(CF2)5), 58.0, 60.9, 66.7, 108.1-119.5 (m, 6 C, (CF2)5CF3), 127.9, 128.1, 128.5,
136.5, 155.7, 172.4; 19F-NMR (471 MHz, CDCl3): δ = -80.8 (t, J = 9.4 Hz), -115.4, -122.0, -122.8,
-123.0, -126.1; MS: (ESI) m/z = 639.27 (M+1).
Ethyl (4S*, 5S*)-5-benzamido-1-(2,2-difluoroethyl)azepane-4-carboxylate, (±)-24a
Colorless oil; yield: 15% (90 mg); Rf =0.48 (n-hexane/EtOAc 2:1); 1H-NMR (500 MHz, CDCl3):
δ = 1.24-1.28 (m, 5H, CH3, H-6), 1.82-1.94 (m, 2H, H-3), 2.08-2.29 (m, 2H, H-2), 2.73-2.83 (m,
3H, H-7, H-4), 2.84-2.94 (m, 3H, CH2CHF2, H-5), 4.12-4.23 (m, 2H, CH2), 4.65-4.76 (brs. 1H,
NH), 5.60-6.25 (tt, 1H, CHF2, 1J = 56.17 Hz, 2J = 54.76 Hz) 7.39-7.84 (m, 5H, Ar-H); 13C-NMR
(126 MHz, CDCl3): δ = 14.1, 27.9, 29.7, 31.9, 47.1, 48.2 (t, 2JC,F = 25.3 Hz, CCHF2), 50.0, 52.3,
52.8, 60.4, 60.6, 60.7, 60.8, 115.4 (t, 1JC,F = 241.2 Hz, CHF2), 126.9, 127.2, 128.5, 128.6, 131.4,
134.5, 166.4, 173.4; 19F-NMR (471 MHz, CDCl3): δ = -123.9 Hz; MS: (ESI) m/z = 355.88 (M+1).
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Ethyl (4S*,5S*)-5-benzamido-1-(2-fluoroethyl)azepane-4-carboxylate, (±)-24b
Colorless oil; yield: 12% (80 mg); Rf =0.5 (n-hexane/EtOAc 2:1); 1H-NMR (500 MHz, CDCl3): δ
= 1.23-1.25 (m, 3H, CH3), 1.26-1.28 (m, 2H, H-3), 1.84-1.93 (m, 2H, H-6), 2.13-2.27 (m, 2H, H-
2), 2.65-2.75 (m, 2H, H-7), 2.79-2.93 (m, 3H, H-4, CH2-CH2F), 4.08-4.19 (m, 2H, CH2CH3), 4.41-
4.57 (dt, 2H, CH2F, 1J = 48.49 Hz, 2J = 27.01 Hz), 4.78-4.86 (m, 1H, H-5), 7.38-7.50 (m, 3H, Ar-
H), 7.63-7.70 (brs. 1H, NH), 7.74-7.82 (m, 5H, Ar-H); 13C-NMR (126 MHz, CDCl3): δ = 14.1,
28.1, 29.7, 31.5, 47.9, 49.6, 51.7, 51.9, 58.5 (d, 2JC,F = 19.3 Hz, CCH2F), 60.7, 81.9 (d 1JC,F = 168.9
Hz, CH2F), 126.9, 127.6, 128.4, 128.7, 131.3, 134.6, 166.3, 173.4; 19F-NMR (471 MHz, CDCl3):
δ = -216.3 Hz; MS: (ESI) m/z = 337.57 (M+1).
Ethyl (4R*, 5S*)-5-benzamido-1-(1,1,1-trifluoropropan-2-yl)azepane-4-carboxylate, (±)-24c
Colorless oil, yield: 27% (100mg); Rf = 0.51 (n-hexane/EtOAc, 6:1); 1H-NMR (500 MHz, CDCl3):
δ = 1.17-1.22 (d, 3H, CH3), 1.28 (t, J = 7.08 Hz, 3H, CH3), 1.81-1.90 (m, 2H, H-6, H-3), 1.98-2.09
(m, 1H, H-6), 2.26-2.37 (m, 1H, H-3), 2.65-2.91 (m, 4H, H-2, H-7), 2.91-3.00 (m, 1H, H-4), 3.12-
3.25 (m, 1H, H-5), 4.11-4.24 (m, 2H, CH2), 4.46-4.58 (m, 1H, NCH), 7.38-7.45 (t, 3H, Ar-H);
7.46-7.51 (brs. 1H, NH), 7.70-7.81 (d, 2H, Ar-H); 13C-NMR (126 MHz, CDCl3): δ = 10.0, 14.1,
27.9, 32.7, 45.9, 47.2, 48.5, 50.9, 60.5, 60.8 (q, 2JC,F = 27.0 Hz, CCF3), 126.9, 127.8 (1JC,F = 285
Hz, CF3),, 128.5, 131.3, 134.6, 166.2, 173.2; 19F-NMR (471 MHz, CDCl3): δ = -72.7 Hz; MS: (ESI)
m/z = 387.62 (M+1).
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(4R*, 5S*)-Ethyl 5-benzamido-1-(3,3,3-trifluoropropyl)azepane-4-carboxylate, (±)-24d
Colorless oil, yield: 38% (240mg); Rf = 0.35 (n-hexane/EtOAc, 6:1); 1H-NMR (500MHz, CDCl3):
δ = 1.26 (t, J = 7.0 Hz, 3H, CH3), 1.82-1.93 (m, 2H, H-6, H-3), 2.03-2.16 (m, 1H, H-6), 2.17-2.30
(m, 3H, H-3, CH2CF3), 2.51-2.61 (m, 2H, H-2), 2.66-2.79 (m, 4H, H-7, NCH2), 2.79-2.88 (m, 1H,
H-4), 4.09-4.22 (m, 2H, OCH2), 4.62-4.74 (m, 1H, H-5), 7.40-7.43 (brs. 1H, NH), 7.43-7.77 (m,
5H, Ar-H); 13C-NMR (126 MHz, CDCl3): δ = 14.1, 27.7, 31.9, 32. (q, 2JC,F = 26.8 Hz, CCF3), 47.1,
50.1, 51.0, 51.3 (d, 3JC,F = 2.7 Hz, CCCF3), 51.6, 60.6, 126.4 (q, 1JC,F =277.0 Hz, CF3), 126.9,




Colorless oil; yield: 27% (200 mg); Rf = 0.28 (n-hexane/EtOAc 2:1); 1H-NMR (500 MHz, CDCl3):
δ = 1.26 (t, J = 7.16 Hz, 3H, CH3), 1.84-1.93 (m, 2H, H-3, H-6), 2.10-2.34 (m, 2H, H-3, H-6), 2.77-
2.87 (m, 2H, H-2), 2.87-2.92 (m, 1H, H-4), 2.92-2.98 (m, 2H, H-7), 3.09-3.29 (m, 2H, CH2CF2),
4.12-4.20 (m, 2H, CH2), 4.61-4.74 (m, 1H, H-5), 7.33-7.44 (m, 3H, Ar-H), 7.45-7.54 (brs. 1H,
NH), 7.74-7.81 (m, 2H, Ar-H); 13C-NMR (126 MHz, CDCl3): δ = 14.1, 27.9, 32.0, 46.9, 50.1, 52.7,
53.4, 57.6 (t, 2JC,F = 20.5 Hz, CCHF2), 60.6, 111.0-121.2 (m, 6C, (CF2)5CF3), 126.9, 128.4, 131.3,
134.5, 166.47, 173.1; 19F-NMR (471 MHz, DMSO-d6): δ = -81.1 (t, J = 9.94 Hz), -117.3, -122.0, -
122.8, -123.5, -126.1; MS: (ESI) m/z = 624 (M+1).
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